secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001558370-24-008491
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences Q1 rev $1.9M (-15% YoY), gross margin up to 59.9%, opex down 51%
--------------------------------------------------------------------------------

- Q1 revenue $1.9M, down 15% YoY; gross margin improved to 59.9% (from 53.5%) due to lower overhead.
- Total operating expenses down 51% YoY; sales & marketing down 53%, G&A down 56%.
- Cost reduction plan expected to cut 2024 opex by ~55% vs 2023; RIF implemented.
- Cash and equivalents $2.5M; net working capital $4.4M.
- Lap-Band 2.0 FLEX launch underway; intragastric balloon patent issued; M&A search with Maxim Group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024008491/0001558370-24-008491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024008491/rsls-20240515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer